Clerkenwell Health’s opening marks a turning point for psychedelic medicine, moving it from university labs into dedicated commercial infrastructure built to carry promising compounds through late-stage clinical trials. The clinic’s first focus is patients facing terminal diagnoses — a population where conventional treatments often fall short, and where earlier psilocybin studies showed lasting reductions in anxiety and depression after just one or two sessions. By serving multiple drug developers at once, the facility could meaningfully accelerate how quickly different psychedelic compounds reach the people who need them. It’s a signal that this field is ready to scale.